CO6251366A2 - Derivados de heteroarilo biciclico fusionados - Google Patents
Derivados de heteroarilo biciclico fusionadosInfo
- Publication number
- CO6251366A2 CO6251366A2 CO09125396A CO09125396A CO6251366A2 CO 6251366 A2 CO6251366 A2 CO 6251366A2 CO 09125396 A CO09125396 A CO 09125396A CO 09125396 A CO09125396 A CO 09125396A CO 6251366 A2 CO6251366 A2 CO 6251366A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- alkyl group
- formula
- optionally substituted
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
Abstract
Un derivado de heteroarilo bicíclico fusionado novedoso, el cual tiene un buen efecto hipoglicémico y trata enfermedades y trastornos metabólicos de azúcar y lípidos mediante receptor activado por proliferador de peroxisoma (PPAR) y y/o evita la generación de estas enfermedades, o una sal farmacológicamente aceptable del mismo. Un compuesto que tiene la siguiente formula general (I) o una sal farmacológicamente aceptable del mismo. [Química para formula 1] (I) en donde R1 representa un grupo C1-6 alquilo, un grupo C6-10 arilo opcionalmente substituido por uno a cinco grupos independientemente seleccionados del grupo substituyente a, etc. R2 representa un grupo C1-6 alquilo, R1 representa un grupo arilo opcionalmente substituido por de 1 e 5 grupos independientemente seleccionado del grupo substituyente a, etc. Q representa un grupo representado por la fórmula -CH- o un átomo de nitrógeno, y el grupo substituyente a incluye un átomo de halógeno, un grupo C1-6 alquilo, un grupo C1-6 hidroxialquilo, etc.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007099413 | 2007-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6251366A2 true CO6251366A2 (es) | 2011-02-21 |
Family
ID=39863835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09125396A CO6251366A2 (es) | 2007-04-05 | 2009-11-05 | Derivados de heteroarilo biciclico fusionados |
Country Status (18)
Country | Link |
---|---|
US (2) | US20100048564A1 (es) |
EP (1) | EP2138484B1 (es) |
JP (1) | JP5294419B2 (es) |
KR (1) | KR20090126286A (es) |
CN (1) | CN101679298B (es) |
AU (1) | AU2008239179B2 (es) |
BR (1) | BRPI0809643A2 (es) |
CA (1) | CA2683089A1 (es) |
CO (1) | CO6251366A2 (es) |
ES (1) | ES2550479T3 (es) |
IL (1) | IL201326A0 (es) |
MX (1) | MX2009010790A (es) |
MY (1) | MY148434A (es) |
NZ (1) | NZ580588A (es) |
RU (1) | RU2456276C2 (es) |
TW (2) | TW200906400A (es) |
WO (1) | WO2008126732A1 (es) |
ZA (1) | ZA200907510B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102341386A (zh) * | 2009-03-05 | 2012-02-01 | 第一三共株式会社 | 吡啶衍生物 |
US20120238759A1 (en) * | 2009-11-26 | 2012-09-20 | Daiichi Sankyo Company, Limited | Method for manufacturing a 6-substituted 1-methyl-1h-benzimidazole derivative and an intermediate of said method |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
JPWO2012033091A1 (ja) | 2010-09-07 | 2014-01-20 | 第一三共株式会社 | 安息香酸エステル類の製造法 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013068486A1 (en) | 2011-11-08 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of male infertility |
EP2809656A2 (en) * | 2011-12-28 | 2014-12-10 | Allergan, Inc. | Benzimidazole derivatives as selective blockers of persistent sodium current |
JP2016079168A (ja) * | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | 9員縮合環誘導体 |
CN107176914B (zh) * | 2016-03-09 | 2022-06-28 | 浙江旭晨医药科技有限公司 | 新型gvs系列化合物及其用途 |
CN108822103A (zh) * | 2018-07-28 | 2018-11-16 | 刘凤娟 | 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
IL118474A (en) * | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
CZ302475B6 (cs) | 1997-10-08 | 2011-06-08 | Sankyo Company Limited | Substituované kumulované heterocyklické slouceniny |
HUP9902721A2 (hu) * | 1997-11-25 | 1999-12-28 | The Procter & Gamble Co. | Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület |
US5968960A (en) * | 1999-01-14 | 1999-10-19 | The Regents Of The University Of California | Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism |
CZ20013593A3 (cs) * | 1999-04-06 | 2002-03-13 | Sankyo Company, Limited | Alfa-Substituované deriváty karboxylových kyselin |
JP4169450B2 (ja) * | 1999-04-07 | 2008-10-22 | 第一三共株式会社 | インスリン抵抗性改善剤 |
TWI284533B (en) * | 1999-05-24 | 2007-08-01 | Sankyo Co | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant |
US6630598B2 (en) * | 2000-07-13 | 2003-10-07 | Sumitomo Chemical Company, Limited | Process for producing N-acylnitroaniline derivative |
JP2002193948A (ja) * | 2000-10-06 | 2002-07-10 | Sankyo Co Ltd | α−置換カルボン酸誘導体を含有する糖尿病治療剤 |
TWI311133B (en) * | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
EP1490058B1 (en) * | 2002-02-21 | 2007-10-10 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
US8299108B2 (en) * | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
AU2003254795A1 (en) * | 2002-08-02 | 2004-02-23 | Sankyo Company, Limited | Resorcinol derivative |
JP2004123711A (ja) | 2002-08-02 | 2004-04-22 | Sankyo Co Ltd | レゾルシノール誘導体 |
JP2004067629A (ja) * | 2002-08-09 | 2004-03-04 | Yamanouchi Pharmaceut Co Ltd | ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体 |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
JP2004315404A (ja) * | 2003-04-15 | 2004-11-11 | Sankyo Co Ltd | ベンゾイミダゾール誘導体を含有する医薬 |
JP2007508382A (ja) | 2003-10-14 | 2007-04-05 | イーライ リリー アンド カンパニー | Pparモジュレータとしてのフェノキシエーテル誘導体 |
EP1798216A4 (en) * | 2004-09-28 | 2008-12-03 | Sankyo Co | INTERMEDIATE PRODUCT OF A 6-SUBSTITUTED 1-METHYL-1H-BENZIMIDAZOLE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF |
CA2642665C (en) * | 2006-02-09 | 2013-01-08 | Daiichi Sankyo Company, Limited | Anti-cancer pharmaceutical composition |
-
2008
- 2008-04-02 NZ NZ580588A patent/NZ580588A/en not_active IP Right Cessation
- 2008-04-02 RU RU2009140769/04A patent/RU2456276C2/ru not_active IP Right Cessation
- 2008-04-02 CN CN2008800189675A patent/CN101679298B/zh not_active Expired - Fee Related
- 2008-04-02 ES ES08739652.9T patent/ES2550479T3/es active Active
- 2008-04-02 TW TW097111934A patent/TW200906400A/zh unknown
- 2008-04-02 AU AU2008239179A patent/AU2008239179B2/en not_active Ceased
- 2008-04-02 CA CA002683089A patent/CA2683089A1/en not_active Abandoned
- 2008-04-02 MX MX2009010790A patent/MX2009010790A/es not_active Application Discontinuation
- 2008-04-02 EP EP08739652.9A patent/EP2138484B1/en not_active Not-in-force
- 2008-04-02 BR BRPI0809643-0A2A patent/BRPI0809643A2/pt not_active IP Right Cessation
- 2008-04-02 WO PCT/JP2008/056541 patent/WO2008126732A1/ja active Application Filing
- 2008-04-02 JP JP2009509273A patent/JP5294419B2/ja not_active Expired - Fee Related
- 2008-04-02 MY MYPI20094121A patent/MY148434A/en unknown
- 2008-04-02 KR KR1020097020618A patent/KR20090126286A/ko not_active Application Discontinuation
- 2008-04-03 TW TW097112101A patent/TW200901981A/zh unknown
-
2009
- 2009-10-01 IL IL201326A patent/IL201326A0/en unknown
- 2009-10-05 US US12/573,625 patent/US20100048564A1/en not_active Abandoned
- 2009-10-26 ZA ZA200907510A patent/ZA200907510B/xx unknown
- 2009-11-05 CO CO09125396A patent/CO6251366A2/es not_active Application Discontinuation
-
2012
- 2012-03-13 US US13/418,796 patent/US20130035337A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0809643A2 (pt) | 2014-11-11 |
AU2008239179A1 (en) | 2008-10-23 |
TW200901981A (en) | 2009-01-16 |
ES2550479T3 (es) | 2015-11-10 |
CN101679298B (zh) | 2013-10-23 |
MX2009010790A (es) | 2009-10-29 |
CA2683089A1 (en) | 2008-10-23 |
US20130035337A1 (en) | 2013-02-07 |
ZA200907510B (en) | 2010-07-28 |
WO2008126732A1 (ja) | 2008-10-23 |
RU2009140769A (ru) | 2011-05-10 |
EP2138484B1 (en) | 2015-08-26 |
IL201326A0 (en) | 2010-05-31 |
CN101679298A (zh) | 2010-03-24 |
JP5294419B2 (ja) | 2013-09-18 |
RU2456276C2 (ru) | 2012-07-20 |
EP2138484A4 (en) | 2012-01-11 |
NZ580588A (en) | 2011-12-22 |
JPWO2008126732A1 (ja) | 2010-07-22 |
US20100048564A1 (en) | 2010-02-25 |
KR20090126286A (ko) | 2009-12-08 |
MY148434A (en) | 2013-04-30 |
EP2138484A1 (en) | 2009-12-30 |
TW200906400A (en) | 2009-02-16 |
AU2008239179B2 (en) | 2011-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6251366A2 (es) | Derivados de heteroarilo biciclico fusionados | |
ES2491140T3 (es) | Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación | |
CO6362003A2 (es) | Derivado de piridina | |
CR20180022A (es) | Derivados etinilo. | |
AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
AR057209A1 (es) | Compuestos para el tratamiento de trastornos inflamatorios y enfermedades microbianas | |
CY1110977T1 (el) | Υποκατεστημενα παραγωγα ινδολης για φαρμακευτικη συνθεση για θεραπεια ασθενειων του αναπνευστικου | |
EA201071370A1 (ru) | Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы | |
BR112013025881A2 (pt) | composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii) | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
ATE552246T1 (de) | Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten | |
AR107010A1 (es) | Derivados de piperidina puenteados | |
AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
AR052314A1 (es) | Compuestos de tienopiridinona como agonistas del receptor 5-ht4 | |
AR083180A1 (es) | Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa | |
AR110001A1 (es) | Derivados heteroarilo bicíclicos | |
AR093408A1 (es) | Derivados de oxazolidin-2-ona-pirimidina | |
EA201270359A1 (ru) | Терапевтическое средство от расстройств настроения | |
ECSP099441A (es) | Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona | |
AR098965A1 (es) | Derivados de sulfonamidas tricíclicas | |
RU2012144438A (ru) | Производные 1-(2-фторбифенил-4-ил)-алкилкарбоновой кислоты для лечения транстиретинового амилоидоза | |
AR062769A1 (es) | Derivados de 5- fenil- nicotilamida | |
EA200700364A1 (ru) | Производные амида кинуреновой кислоты как антагонисты nr2b подтипа рецептора nmda | |
AR078120A1 (es) | Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida y composiciones farmaceuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |